Sentinel-Lymphknoten-Biopsie – Schritt für Schritt

Die Detektion und Darstellung des Sentinel-Lymphknotens ist eine etablierte Methode in der Diagnostik des Mammakarzinoms. Radioaktive Tracer oder auch Farbstoffe werden zur Visualisierung der Lymphknoten eingesetzt. Der folgende Beitrag führt Schritt für Schritt durch eine Sentinel-Lymphknoten-Biopsie. Dabei werden die Vorteile der Verwendung von Indocyaningrün deutlich.

Schlüsselwörter

Sentinel-Lymphknoten - Biopsie - Mammakarzinom - Indikation - Indocyaningrün - Durchführung

• Literatur

• 1 Robert Koch-Institut. Zentrum für Krebsregisterdaten. Brustkrebs (Mammakarzinom). Zugriff am 15. Januar 2025 unter: https://www.krebsdaten.de/Krebs/DE/Content/Krebsarten/Brustkrebs/brustkrebs_node.html
• 2 Fisher B, Redmond C, Fisher ER. et al. Ten-year results of a randomized clinical trial comparing radical mastectomy and total mastectomy with or without radiation. N Engl J Med 1985; 312: 674-681
• 3 Krag DN, Weaver DL, Alex JC. et al. Surgical resection and radiolocalization of the sentinel lymph node in breast cancer using a gamma probe. Surg Oncol 1993; 2: 335-339 discussion 340
• 4 Kuehn T, Bembenek A, Decker T. et al. A concept for the clinical implementation of sentinel lymph node biopsy in patients with breast carcinoma with special regard to quality assurance. Cancer 2005; 103: 451-461
• 5 Krag D, Weaver D, Ashikaga T. et al. The Sentinel Node in Breast Cancer — A Multicenter Validation Study. N Engl J Med 1998; 339: 941-946
• 6 Veronesi U, Paganelli G, Viale G. et al. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med 2003; 349: 546-553
• 7 Krag DN, Anderson SJ, Julian TB. et al. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol 2010; 11: 927-933
• 8 Albertini JJ. Lymphatic Mapping and Sentinel Node Biopsy in the Patient With Breast Cancer. JAMA 1996; 276: 1818-1822
• 9 Bromham N, Schmidt-Hansen M, Astin M. et al. Axillary treatment for operable primary breast cancer. Cochrane Database Syst Rev 2017; (01) CD004561
• 10 Chagpar A, Martin 3rd RC, Chao C. et al. Validation of subareolar and periareolar injection techniques for breast sentinel lymph node biopsy. Arch Surg 2004; 139: 614-618 discussion 618–620
• 11 Tanis PJ, Nieweg OE, Valdes Olmos RA. et al. Anatomy and physiology of lymphatic drainage of the breast from the perspective of sentinel node biopsy. J Am Coll Surg 2001; 192: 399-409
• 12 Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF). S3-Leitlinie Früherkennung, Diagnose, Therapie und Nachsorge des Mammakarzinoms, Version 4.4, AWMF Registernummer: 032–045OL. 2021 Zugriff am 15. Januar 2025 unter: https://register.awmf.org/de/leitlinien/detail/032-045OL
• 13 Arbeitsgemeinschaft Gynäkologische Onkologie e. V. (AGO). Leitlinien & Empfehlungen | Guidelines. Empfehlungen gynäkologische Onkologie Kommission Mamma. Zugriff am 15. Januar 2025 unter: https://www.ago-online.de/leitlinien-empfehlungen/leitlinien-empfehlungen/kommission-mamma
• 14 Intra M, Viale G, Vila J. et al. Second Axillary Sentinel Lymph Node Biopsy for Breast Tumor Recurrence: Experience of the European Institute of Oncology. Ann Surg Oncol 2015; 22: 2372-2377
• 15 Kaminski A, Amr D, Kimbrell ML. et al. Lymphatic mapping in patients with breast cancer and previous augmentation mammoplasty. Am Surg 2007; 73: 981-983
• 16 Gerber B, Heintze K, Stubert J. et al. Axillary lymph node dissection in early-stage invasive breast cancer: is it still standard today?. Breast Cancer Res Treat 2011; 128: 613-624
• 17 Gentilini OD, Botteri E, Sangalli C. et al. Sentinel Lymph Node Biopsy vs No Axillary Surgery in Patients With Small Breast Cancer and Negative Results on Ultrasonography of Axillary Lymph Nodes: The SOUND Randomized Clinical Trial. JAMA Oncol 2023; 9: 1557-1564
• 18 Reimer T, Stachs A, Veselinovic K. et al. Axillary Surgery in Breast Cancer – Primary Results of the INSEMA Trial. N Engl J Med 2024;
• 19 Singletary SE. Surgical management of inflammatory breast cancer. Semin Oncol 2008; 35: 72-77
• 20 Hidar S, Bibi M, Gharbi O. et al. Sentinel lymph node biopsy after neoadjuvant chemotherapy in inflammatory breast cancer. Int J Surg 2009; 7: 272-275
• 21 Douek M, Klaase J, Monypenny I. et al. Sentinel node biopsy using a magnetic tracer versus standard technique: the SentiMAG Multicentre Trial. Ann Surg Oncol 2014; 21: 1237-1245
• 22 Grischke EM, Rohm C, Hahn M. et al. ICG Fluorescence Technique for the Detection of Sentinel Lymph Nodes in Breast Cancer: Results of a Prospective Open-label Clinical Trial. Geburtshilfe Frauenheilkd 2015; 75: 935-940
• 23 Thill M, Kurylcio A, Welter R. et al. The Central-European SentiMag study: sentinel lymph node biopsy with superparamagnetic iron oxide (SPIO) vs. radioisotope. Breast 2014; 23: 175-179
• 24 Perenyei M, Barber ZE, Gibson J. et al. Anaphylactic Reaction Rates to Blue Dyes Used for Sentinel Lymph Node Mapping: Systematic Review and Meta-analysis. Ann Surg 2021; 273: 1087-1093
• 25 Nguyen CL, Zhou M, Easwaralingam N. et al. Novel Dual Tracer Indocyanine Green and Radioisotope Versus Gold Standard Sentinel Lymph Node Biopsy in Breast Cancer: The GREENORBLUE Trial. Ann Surg Oncol 2023; 30: 6520-6527
• 26 Motomura K, Inaji H, Komoike Y. et al. Combination technique is superior to dye alone in identification of the sentinel node in breast cancer patients. J Surg Oncol 2001; 76: 95-99
• 27 Krikanova M, Biggar M, Moss D. et al. Accuracy of sentinel node biopsy for breast cancer using blue dye alone. Breast J 2010; 16: 384-388
• 28 Bargon CA, Huibers A, Young-Afat DA. et al. Sentinel Lymph Node Mapping in Breast Cancer Patients Through Fluorescent Imaging Using Indocyanine Green: The INFLUENCE Trial. Ann Surg 2022; 276: 913-920
• 29 Ballardini B, Santoro L, Sangalli C. et al. The indocyanine green method is equivalent to the (9)(9)mTc-labeled radiotracer method for identifying the sentinel node in breast cancer: a concordance and validation study. Eur J Surg Oncol 2013; 39: 1332-1336
• 30 Kedrzycki MS, Leiloglou M, Ashrafian H. et al. Meta-analysis Comparing Fluorescence Imaging with Radioisotope and Blue Dye-Guided Sentinel Node Identification for Breast Cancer Surgery. Ann Surg Oncol 2021; 28: 3738-3748
• 31 Bourgeois P, Roman MM, Schweicher J. et al. Lymphatic Alterations Under Tattoos: Preliminary Reports of One Observational Study. Clin Cosmet Investig Dermatol 2023; 16: 257-265
• 32 Rubio IT, Rodriguez-Revuelto R, Espinosa-Bravo M. et al. A randomized study comparing different doses of superparamagnetic iron oxide tracer for sentinel lymph node biopsy in breast cancer: The SUNRISE study. Eur J Surg Oncol 2020; 46: 2195-2201
• 33 Christenhusz A, Pouw JJ, Simonis FFJ. et al. Breast MRI in patients after breast conserving surgery with sentinel node procedure using a superparamagnetic tracer. Eur Radiol Exp 2022; 6: 3
• 34 Aribal E, Celik L, Yilmaz C. et al. Effects of iron oxide particles on MRI and mammography in breast cancer patients after a sentinel lymph node biopsy with paramagnetic tracers. Clin Imaging 2021; 75: 22-26
• 35 Rubio IT, Diaz-Botero S, Esgueva A. et al. The superparamagnetic iron oxide is equivalent to the Tc99 radiotracer method for identifying the sentinel lymph node in breast cancer. Eur J Surg Oncol 2015; 41: 46-51
• 36 Houpeau JL, Chauvet MP, Guillemin F. et al. Sentinel lymph node identification using superparamagnetic iron oxide particles versus radioisotope: The French Sentimag feasibility trial. J Surg Oncol 2016; 113: 501-507